Tiffany Pinckney remembers the fear when COVID-19 stole her breath. So when she recovered, the New York City mother became one of the country's first survivors to donate her blood to help treat other seriously ill patients.
It is definitely overwhelming to know that in my blood, there may be answers, Pinckney told The Associated Press.
Doctors around the world are dusting off a century-old treatment for infections: Infusions of blood plasma teeming with immune molecules that helped survivors beat the new coronavirus. There's no proof it will work. But former patients in Houston and New York were early donors, and now hospitals and blood centers are getting ready for potentially hundreds of survivors to follow.
There's a tremendous call to action, said Dr. David Reich, president of New York's Mount Sinai Hospital, which declared Pinckney recovered and raced to collect her blood.
People feel very helpless in the face of this disease. And this is one thing that people can do to help their fellow human beings. As treatments get underway, we just hope it works," he said.
What the history books call convalescent serum was most famously used during the 1918 flu pandemic, and also against measles, bacterial pneumonia and numerous other infections before modern medicine came along. Why? When infection strikes, the body starts making proteins called antibodies specially designed to target that germ.
Those antibodies float in survivors' blood specifically plasma, the yellowish liquid part of blood for months, even years.
When new diseases erupt and scientists are scrambling for vaccines or drugs, it's a stopgap measure that we can put into place quickly, said Dr. Jeffrey Henderson of Washington University School of Medicine in St. Louis, who is helping to develop a nationwide study.
This is not a cure per se, but rather it is a way to reduce the severity of illness, Henderson said.
Doctors don't know how long survivors' antibodies against COVID-19 will persist. But for now, they're the safest ones on the street, said Dr. Rebecca Haley of Bloodworks Northwest in Seattle, which is working to identify donors. "We would not be making a dent in their antibody supply for themselves."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
